Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.

Haematologica·2026
Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Maternal opioids downregulate adiponectin receptor signaling and alter growth in offspring: pilot study.

Frontiers in pediatrics·2026

Related Experiment Video

Updated: Sep 8, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K

An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.

Angie Mae Rodday1, Andrew M Evens2, Matthew J Maurer3

  • 1Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston.

NEJM Evidence
|June 19, 2025
PubMed
Summary

A new predictive model, the Early-Stage cHL International Prognostication Index (E-HIPI), has been developed to forecast 2-year progression-free survival in classic Hodgkin

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

193
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.1K

Related Experiment Videos

Last Updated: Sep 8, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

193
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.1K

Area of Science:

  • Oncology
  • Clinical Prediction Modeling
  • Hematologic Malignancies

Background:

  • No existing predictive model for early-stage classic Hodgkin's lymphoma (cHL).
  • Need for a tool to predict progression-free survival (PFS) in early-stage cHL patients.

Purpose of the Study:

  • To develop and validate the Early-Stage cHL International Prognostication Index (E-HIPI).
  • To predict 2-year PFS in adults with newly diagnosed early-stage cHL.

Main Methods:

  • Development using Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) guidelines.
  • Utilized data from 3000 patients in international phase III clinical trials.
  • External validation in 2360 patients from international cHL registries.
  • Cox model with backward elimination for variable selection.

Main Results:

  • E-HIPI model includes sex, maximum tumor diameter, hemoglobin, and albumin levels.
  • Optimism-corrected C-statistic of 0.63 in development cohort.
  • Validated model showed similar discrimination (C-statistic 0.63) and calibration in external cohorts.
  • Higher E-HIPI scores correlated with worse PFS, outperforming EORTC status.

Conclusions:

  • E-HIPI is a validated prediction model for early-stage cHL using objective variables.
  • Male sex, lower hemoglobin/albumin, and larger tumor diameter predict worse PFS.
  • Online risk calculators are available for clinical use.